> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Klobuchar Targets Improper Patent Listings
- URL: https://www.fdaweb.com/klobuchar-targets-improper-patent-listings/
- Published: 2024-01-19T12:00:00.000Z
- Updated: 2026-09-14T14:20:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156173

Senator **Amy Klobuchar** (D-MN) has sent letters to six pharmaceutical companies — Abbvie, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mylan-Viatris, and Teva — requesting they remove all patents identified by the Federal Trade Commission (FTC) as improperly or inaccurately listed in FDA’s *Orange Book* by the end of the month.

Klobuchar says her requests are a follow-up to an 11/2023 action where the FTC sent Warning Letters to 10 drug companies identifying more than 100 patents that the recipients improperly listed in the *Orange Book*. “A number of pharmaceutical companies have removed these patents from the *Orange Book* in response to the FTC’s warning letters, but most have failed to act,” she says in a [statement](https://www.klobuchar.senate.gov/public/index.cfm/news-releases?ID=AE93371A-CA7D-48CC-8A36-D822A3455E19&ref=fdaweb.com). “The FTC found that improperly listing patents in the FDA *Orange Book* to deter generic competition can violate antitrust laws.”

The full text of the letters can be found [here](https://urldefense.com/v3/%5F%5Fhttps:/drive.google.com/drive/folders/1rwSmj2WnSPzylCBOb-yJ%5F8sGNBUCXaSx?usp=sharing%5F%5F;!!BspMT6SJLSDJ!K6sE3Dfuw7sMRuoU0BouS8RKq%5F1XVnCMQMCpoVSMHGvmt2icxhu%5FjYT3R8Nr9bEVVpT3A0QoscaBcYgvb27UVxxu0Z1OAwTJt6AMTO403g%24&ref=fdaweb.com).